Fierce Biotech

Moderna scraps congenital virus program after vaccine shows little protective effect in phase 3

Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women ...
Stocktwits on MSN

Moderna Stock Slides After-Hours On CMV Vaccine Failure In Phase 3 Trial — Retail Traders Warn Of ‘Endless’ Cash Burn

Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a ...
GlobalData on MSN

Moderna scraps mRNA vaccine in congenital CMV on Phase III failure

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...
Investor's Business Daily on MSN

Moderna Topples, Threatening Its 50-Day Line, After A Key Vaccine Bites The Dust

Moderna stock toppled Thursday after the biotech company's experimental CMV vaccine failed in a Phase 3 study of 7,500 women.
pharmaphorum

Moderna drops mRNA jab for CMV after phase 3 fail

Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital cytomegalovirus (CMV) infections – once ...